Results 61 to 70 of about 4,256 (179)

Semaglutide Therapy and Cardiorenal Risk Management in Type 2 Diabetes: hsCRP as a Biomarker of Risk

Diabetology
Background: Inflammation plays a key role in the pathogenesis of type 2 diabetes (T2D) and the associated cardiovascular complications. High-sensitivity C-reactive protein (hsCRP) is a widely used marker of systemic inflammation as well as a predictor of
Nikolay Krasimirov Kostadinov, Tcvetelina Totomirova, Boyan Ivanov Nonchev   +2 more
doaj   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

SGLT2 Inhibitors in Heart Failure with Coexisting Chronic Kidney Disease

Journal of Education, Health and Sport
Background. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evolved from their origins as antihyperglycemic agents to become a cornerstone of cardiorenal therapy.
Nikodem Cieleban, Michał Rucki, Aleksandra Rucka   +2 more
doaj   +1 more source

Evaluation of a secondary care multidisciplinary clinic for adults with early‐onset type 2 diabetes at high risk in Leicester, Leicestershire and Rutland

Diabetic Medicine, EarlyView.
Abstract Background Clinical services for adults with early‐onset type 2 diabetes (EOT2D) are in urgent need of improvement. Methods We evaluated a multi‐disciplinary clinic for individuals with EOT2D at high risk (HbA1c >9%/triglyceride >20 mmol/L), providing 2–3 flexibly arranged consultations per individual between March 2024 and September 2025 ...
Jonathan Goldney, Malak Hamza, Priscilla Sarkar, Harriet Morgan, Nicole Green, James Ridgeway, Victoria Alabraba, Laura Willcocks, Krupali Chandracant, Kashmala Javed, Rhys O'Callaghan, Finley Turner, Samuel Seidu, Claire L. Meek, Melanie J. Davies   +14 more
wiley   +1 more source

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

Diabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo, Bianca Aparecida Siqueira, Luiz Felipe Azevedo Marques, Lucas Silva Mello, Fernando Augusto Lima Marson   +4 more
wiley   +1 more source

Exploring the Mechanism of Cardiorenal Protection with Finerenone Based on Network Pharmacology

Cardiorenal Medicine
Introduction: Large prospective trials have demonstrated that finerenone could reduce the risk of cardiovascular death and progression of renal failure among patients with chronic kidney disease associated heart failure and/or type 2 diabetes mellitus (T2DM). The aim of this study was to explore the molecular mechanism of finerenone in the treatment of
Yachen, Si, Ying, Zhu, Jing, Liu, Shuyu, Liu, Xiaomin, Cai, Ying, Gu, Hanqing, Li, Fang, Pan, Wenjuan, Wang, Jianying, Shangguan, Rui, Liu, Chunsheng, Xi, Lijun, Wang   +12 more
openaire   +2 more sources

Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes

Diabetic Medicine, EarlyView.
Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLT2i) have proven cardiorenal benefits in type 2 diabetes and are promising as adjunct‐to‐insulin therapy in participants with type 1 diabetes (T1D). However, clinical use in T1D has been limited owing to a lack of regulatory approval and the augmented risk of diabetic ketoacidosis (DKA ...
Julia Fielden, Pam Leblanc, Chloe Parezanovic, Vikas S. Sridhar, Bruce A. Perkins, David Z. Cherney, David J. T. Campbell   +6 more
wiley   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest, Priyanka Majety, Stéphanie B. Mayer, Om P. Ganda   +3 more
wiley   +1 more source

Quality of Diabetes Care Among Older Adults in Germany—Results of the Study on Health of Older People 2022/2023 Compared With Previous National Health Surveys

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The study aims (1) to evaluate the quality of diabetes care considering guideline‐recommended medical therapies, cardiometabolic factors, and self‐management of health behaviours among older adults with diabetes in Germany, and (2) to examine time trends.
Yong Du, Giselle Sarganas, Beate Gaertner, Maike Buchmann, Judith Fuchs, Hannelore Neuhauser, Christin Heidemann   +6 more
wiley   +1 more source

Aliskiren and valsartan combination therapy for the management of hypertension

Vascular Health and Risk Management, 2010
Benjamin J EpsteinDepartments of Pharmacotherapy and Translational Research and Medicine, Colleges of Pharmacy and Medicine, University of Florida, Gainesville, Florida, USA and East Coast Institute for Research, Jacksonville, Florida, USAAbstract ...
Benjamin J Epstein
doaj